KIT and neuroblastoma: Immunohistochemical studies have found that 15–30% of all NBs are KIT-positive, while PCR data suggest that KIT is expressed in 40–80% of these tumours, depending on the specific study [142,143,144], and about half of KIT-positive NB tumours also express SCF [142].